NEW YORK (GenomeWeb News) – Epigenomics today reported that revenues in the second quarter fell 57 percent year over year.

The molecular diagnostics firm posted €156,000 ($192,992) in revenues during the three months ended June 30, down from €364,000 a year ago as it recognized no R&D revenues in the recently completed quarter while product sales and licensing income fell year over year.

Epigenomics' net loss for the quarter widened to €3.4 million from €3.0 million in Q2 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.